PH30813A - Novel method of progesterone and effect thereof. - Google Patents

Novel method of progesterone and effect thereof.

Info

Publication number
PH30813A
PH30813A PH49001A PH49001A PH30813A PH 30813 A PH30813 A PH 30813A PH 49001 A PH49001 A PH 49001A PH 49001 A PH49001 A PH 49001A PH 30813 A PH30813 A PH 30813A
Authority
PH
Philippines
Prior art keywords
progesterone
serum
low levels
effect
novel method
Prior art date
Application number
PH49001A
Other languages
English (en)
Inventor
William J Bologna
Howard L Levine
Original Assignee
Columbia Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22402302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH30813(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Inc filed Critical Columbia Lab Inc
Publication of PH30813A publication Critical patent/PH30813A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
PH49001A 1993-09-15 1994-09-15 Novel method of progesterone and effect thereof. PH30813A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/122,371 US5543150A (en) 1993-09-15 1993-09-15 Method of progesterone delivery and affect thereof

Publications (1)

Publication Number Publication Date
PH30813A true PH30813A (en) 1997-10-17

Family

ID=22402302

Family Applications (1)

Application Number Title Priority Date Filing Date
PH49001A PH30813A (en) 1993-09-15 1994-09-15 Novel method of progesterone and effect thereof.

Country Status (27)

Country Link
US (1) US5543150A (fi)
EP (1) EP0719146B1 (fi)
JP (1) JP3143474B2 (fi)
KR (1) KR100278553B1 (fi)
AT (1) ATE174796T1 (fi)
BR (1) BR9407475A (fi)
CA (1) CA2171939C (fi)
CO (1) CO4290332A1 (fi)
DE (1) DE69415543T2 (fi)
DK (1) DK0719146T3 (fi)
ES (1) ES2126783T3 (fi)
FI (1) FI115444B (fi)
GR (1) GR3029314T3 (fi)
HU (1) HU221583B (fi)
IL (1) IL110972A (fi)
LT (1) LT4072B (fi)
LV (1) LV11527B (fi)
MA (1) MA23329A1 (fi)
MY (1) MY111484A (fi)
NO (1) NO308585B1 (fi)
NZ (1) NZ273816A (fi)
PE (1) PE50795A1 (fi)
PH (1) PH30813A (fi)
RU (1) RU2148393C1 (fi)
UA (1) UA37244C2 (fi)
WO (1) WO1995007699A1 (fi)
ZA (1) ZA947073B (fi)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869081A (en) * 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
US5985861A (en) * 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US6602487B1 (en) 1997-02-26 2003-08-05 Dimera Incorporated Methods and tests for producing and for inhibiting coronary artery vasospasms
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
EP1356806A1 (en) * 1997-09-12 2003-10-29 Columbia Laboratories (Bermuda) Limited A pharmaceutical composition for treating dysmenorrhea and premature labor
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
JP2001519381A (ja) * 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド 子宮収縮管理のためのｃｓａｉｄｔｍ化合物の使用
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
WO1999059595A1 (en) * 1998-05-20 1999-11-25 Wiley Teresa S Progesterone treatment of cancer
US20070178139A1 (en) * 1998-11-18 2007-08-02 Yankov Vladimir I Vaginally administratable progesterone-containing tablets and method for preparing same
IL127129A (en) 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US6479045B2 (en) 1999-12-22 2002-11-12 Columbia Laboratories, Inc. Vaginal pH buffering for preventing miscarriage and premature labor, by treating or preventing bacterial vaginosis
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US7547433B2 (en) * 2001-02-15 2009-06-16 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7709026B2 (en) * 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
DE602004026173D1 (de) * 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
CN1845723B (zh) * 2003-09-03 2010-07-21 迷斯康贸易有限公司 子宫内膜异位症的治疗方法
CN101849906A (zh) * 2003-09-03 2010-10-06 迷斯康贸易有限公司 子宫内膜异位症的治疗方法
US10016442B2 (en) * 2005-06-16 2018-07-10 Allergan Pharmaceuticals International Limited Estrogen compositions for vaginal administration
WO2006138735A2 (en) * 2005-06-16 2006-12-28 Warner Chilcott Company, Inc. Gel compositions for topical administration
BRPI0711525A2 (pt) * 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
ES2310968B1 (es) 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.
TW200918099A (en) * 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
GB0723882D0 (en) * 2007-12-07 2008-01-23 Univ Leicester Methods for the detection of a threatened miscarriage
DK2359807T3 (en) * 2008-02-04 2017-10-16 Ferring Bv Monolithic vaginal rings comprising progesterone and methods of preparation and use thereof
US9107696B2 (en) 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
US8421747B2 (en) 2008-09-24 2013-04-16 Microsoft Corporation Object detection and user settings
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
JP5894143B2 (ja) * 2010-03-22 2016-03-23 リプロス セラピューティクス インコーポレイテッド 抗黄体ホルモンの無毒送達のための組成物および方法
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8435972B2 (en) 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
WO2013010915A1 (en) * 2011-07-15 2013-01-24 Universiteit Gent Intravaginal delivery system
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX367596B (es) * 2012-01-26 2019-08-27 Therapeuticsmd Inc Tratamientos transdermicos de sustitucion hormonal.
ES2701400T3 (es) 2012-05-31 2019-02-22 Repros Therapeutics Inc Formulaciones para la administración vaginal de antiprogestinas
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103239389A (zh) * 2013-06-03 2013-08-14 南京泽恒医药技术开发有限公司 一种治疗先兆性流产的黄体酮缓释凝胶的制备方法
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
MX2017016823A (es) 2015-06-22 2018-03-12 Lipocine Inc Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IL271596B1 (en) * 2017-06-22 2024-03-01 Viramal Ltd An emulsion preparation that includes danzol for use in the treatment of bread mucosa conditions
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3588620A (en) * 1969-08-06 1971-06-28 Gen Electric Electrical control device panel assembly with multifunctional insulating support means
EP0163696B1 (en) * 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US4916574A (en) * 1989-06-06 1990-04-10 Siemens Energy & Automation, Inc. Panelboard bus bar arrangement
DE69014081T2 (de) * 1989-10-31 1995-03-30 Columbia Lab Inc Mittel zur Feuchthaltung vaginalen Gewebes.
EP0599888A1 (de) * 1991-08-05 1994-06-08 Trawöger, Werner Mittel gegen beläge an benetzten oberflächen
TWI354439B (en) 2007-06-04 2011-12-11 Holtek Semiconductor Inc Ac signal producer and method thereof
US7862282B2 (en) 2008-07-24 2011-01-04 Autoliv Asp, Inc. Separation fastener with segmented washer

Also Published As

Publication number Publication date
ZA947073B (en) 1995-05-02
DE69415543D1 (de) 1999-02-04
HUT76824A (en) 1997-11-28
LT4072B (en) 1996-11-25
NO308585B1 (no) 2000-10-02
JP3143474B2 (ja) 2001-03-07
FI115444B (fi) 2005-05-13
LV11527A (lv) 1996-10-20
US5543150A (en) 1996-08-06
EP0719146A1 (en) 1996-07-03
MY111484A (en) 2000-06-30
NO961044L (no) 1996-05-14
RU2148393C1 (ru) 2000-05-10
JPH09502724A (ja) 1997-03-18
IL110972A0 (en) 1994-11-28
HU221583B (hu) 2002-11-28
FI961221A (fi) 1996-05-14
IL110972A (en) 1998-03-10
FI961221A0 (fi) 1996-03-15
MA23329A1 (fr) 1995-04-01
DE69415543T2 (de) 1999-06-17
NZ273816A (en) 2007-09-28
AU7726194A (en) 1995-04-03
DK0719146T3 (da) 1999-08-23
WO1995007699A1 (en) 1995-03-23
CA2171939A1 (en) 1995-03-23
PE50795A1 (es) 1996-01-19
LT96027A (en) 1996-07-25
GR3029314T3 (en) 1999-05-28
AU689133B2 (en) 1998-03-26
LV11527B (en) 1997-02-20
NO961044D0 (no) 1996-03-14
ATE174796T1 (de) 1999-01-15
ES2126783T3 (es) 1999-04-01
UA37244C2 (uk) 2001-05-15
KR100278553B1 (ko) 2001-01-15
BR9407475A (pt) 1996-11-12
CA2171939C (en) 2002-01-01
HU9600669D0 (en) 1996-05-28
EP0719146B1 (en) 1998-12-23
CO4290332A1 (es) 1996-04-17

Similar Documents

Publication Publication Date Title
PH30813A (en) Novel method of progesterone and effect thereof.
GR3030317T3 (en) Sulfonate and carbamate derivatives of 3-aroylbenzo (beta) thiophenes.
AU2332288A (en) Compounds having antiprogestational and anti-estrogenic activities for induction of labor and for termination of pregnancy, as well as for the treatment of gynaecological disorders
BG101349A (en) Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
MY113079A (en) Estrogen agonists as remedies for cardiovascular diseases
HUT72080A (en) Hormone replacement therapy
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
GR3030164T3 (en) Treatment of ovarian estrogen dependent conditions
EP0894000A4 (en) METHOD FOR THE ADMINISTRATION OF ESTROGENS
MY101856A (en) Contraceptive method and kit.
UA29349A (uk) Спосіб лікування ановуляторної неплідності